Elinzanetant is an orally active, non-hormonal neurokinin receptor antagonist developed for the treatment of menopausal vasomotor symptoms, including hot flashes and night sweats. It acts on the neurokinin signaling pathway involved in the regulation of thermoregulatory processes.
Elinzanetant is a dual NK1 and NK3 receptor antagonist, meaning that it blocks the activity of neurokinin-1 and neurokinin-3 receptors. This mechanism is being utilized in the development of non-hormonal therapies for menopausal vasomotor symptoms.
Elinzanetant is a small-molecule pharmaceutical compound with the CAS Registry Number 1290182-56-5.
Elinzanetant API is a pharmaceutical active ingredient used in pharmaceutical research and development involving neurokinin receptor antagonists and non-hormonal treatment approaches for menopausal vasomotor symptoms.
Its selective activity against NK1 and NK3 receptors makes elinzanetant an important compound in research focused on neurokinin-mediated thermoregulation and menopausal symptoms.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |